SCHEMBL16797151

SCHEMBL16797151

CCOC(=O)c1ccc(NNC(=O)c2ccccc2N)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.58
▸ HSD17B10 Q99714 2/20 0.58
▸ MEN1 O00255 6/20 0.57
▸ KMT2A Q03164 6/20 0.57
▸ SMN1; SMN2 Q16637 5/20 0.57
▸ GAA P10253 3/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ LMNA P02545 3/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ MAOA P21397 1/20 0.50
▸ CA1 P00915 3/20 0.49
▸ CA2 P00918 3/20 0.49
▸ CA9 Q16790 2/20 0.48
▸ CA12 O43570 1/20 0.48
▸ ESR1 P03372 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ ESR2 Q92731 1/20 0.48
▸ CA14 Q9ULX7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30539412 0.87 ALDH1A1 (0.76) ALDH1A1HSD17B10MEN1KMT2ASMN1; SMN2
SCHEMBL16797142 0.81 ALDH1A1 (0.51) ALDH1A1HSD17B10MEN1KMT2ASMN1; SMN2
SCHEMBL9011618 0.78 SMN1; SMN2 (0.61) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
Ethyl Anthranilate SCHEMBL28249371 0.78 ALDH1A1 (0.84) ALDH1A1HSD17B10MEN1KMT2ASMN1; SMN2
SCHEMBL28849404 0.77 SMN1; SMN2 (0.72) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL14157352 0.77 CA1 (0.62) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL952169 0.76 ALDH1A1 (0.61) ALDH1A1HSD17B10MEN1KMT2ASMN1; SMN2
SCHEMBL2384508 0.76 CA1 (0.61) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL2255472 0.76 MAPK13 (0.60) ALDH1A1HSD17B10MEN1KMT2ASMN1; SMN2
SCHEMBL14855618 0.76 HSD17B10 (0.69) ALDH1A1HSD17B10SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3080090-B1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2018-01-31 — — EP disclosed
US-9682977-B2 Bicyclic heteroaryl indole analogues useful as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2017-06-20 — — US disclosed
US-9682977-B2 Bicyclic heteroaryl indole analogues useful as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2017-06-20 — — US disclosed
US-9682977-B2 Bicyclic heteroaryl indole analogues useful as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2017-06-20 — — US disclosed
US-20160326163-A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2016-11-10 — — US disclosed
US-20160326163-A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2016-11-10 — — US disclosed
EP-3080090-A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2016-10-19 — — EP disclosed
WO-2015087234-A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2015-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326163-A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS RORA, RORB, RORC ALDH1A1 1211/4885HSD17B10 1284/4885MEN1 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback